RecruitingNot ApplicableNCT06528171

Covid-19 Long Immunité IMagerie (CLIIM)

Specific Markers of Covid-long Syndrome: Identifying the Mechanisms Involved With a View to Defining Diagnostic Criteria

Sponsor

Centre Hospitalier Universitaire de Nice

Enrollment

200 participants

Start Date

Dec 6, 2024

Study Type

INTERVENTIONAL

Conditions

COVID Long-Haul

Summary

Covid-long pathology affects a large number of patients, and represents a major medical, economic and societal challenge. To date, we have no objective criterion for a definitive diagnosis, nor any predictive tool for monitoring the evolution of Covid-long. Based on recruitment from the infectious diseases department of Nice University Hospital, the investigator's team wants to conduct an innovative pathophysiological study to better define the disease and identify specific biomarkers that could subsequently be used as a diagnostic tool for Covid-long. 120 participants will be initially included for the model learning phase: 60 controls in the CL- cohort and 60 patients in the CL+ cohort. Then 80 patients (40 CL+ and 40 Cl-) will be enrolled for the model validation phase.

Eligibility

Min Age: 18 Years

Inclusion Criteria4

FOR CL+ PATIENTS
Case definition in line with WHO Delphi process
History of acute COVID-19, mild, moderate or severe (episode at least 3 months at the time of inclusion).
Absence of persistent symptoms more than 3 months after first Covid symptoms (or mild not affecting daily activities).

Exclusion Criteria9

History of chronic fatigue syndrome diagnosed before or after Covid.
History of progressive psychiatric pathology.
History of acute Covid requiring admission to intensive care and mechanical ventilation.
No social security affiliation.
FOR CONTROL (CL-)
History of progressive psychiatric pathology.
History of acute Covid requiring admission to intensive care and mechanical ventilation.
No social security affiliation.
Pregnant or breast-feeding.

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.